甲胎蛋白应答在肝细胞癌治疗中的预后价值

贾佳; 祁兴顺; 韩国宏

doi:10.3969/j.issn.1001-5256.2013.08.006

甲胎蛋白应答在肝细胞癌治疗中的预后价值

DOI: 10.3969/j.issn.1001-5256.2013.08.006

第四军医大学西京消化病医院消化介入科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 3532
- HTML全文浏览量: 22
- PDF下载量: 1018
- 被引次数: 0
出版历程
- 收稿日期: 2013-03-13
- 出版日期: 2013-08-20

Prognostic value of α-fetoprotein response in treatment of hepatocellular carcinoma

摘要

摘要:
肝细胞癌(HCC)是最常见的肝脏恶性肿瘤。因其恶性程度高、预后差,准确评估患者的治疗效果及预后情况至关重要。尽管目前影像学是肝癌预后评估的标准方法,但其仍存在诸多局限性。甲胎蛋白是重要的肝癌肿瘤标志物,广泛的应用于肝癌的筛查、诊断及预后评价。总结了甲胎蛋白应答在评判肝癌患者预后的相关文献。整体上,甲胎蛋白应答在肝癌患者接受射频消融、肝动脉化疗栓塞、钇90放射性栓塞、索拉菲尼等分子靶向药物、全身化疗、肝动脉灌注化疗或同步放化疗等治疗后具有良好的预后价值。
- 癌,肝细胞 /
- 甲胎蛋白类 /
- 预后
Abstract:
Primary hepatocellular carcinoma (HCC) is the most common malignant tumor of the liver.Accurate assessment of treatment outcome and prognosis in HCC patients is very important due to its high malignancy and poor prognosis.Currently, radiological imaging, though a standard method for prognostic evaluation of HCC, has a lot of limitations.As an important serological marker of HCC, alpha-fetoprotein (AFP) has been widely used in the screening, diagnosis, and prognostic evaluation of HCC.The studies regarding the prognostic value of AFP response in HCC patients were summarized.Generally, AFP has good prognostic value in HCC patients treated with radiofrequency ablation, transarterial chemoembolization, yttrium-90 radioembolization, molecular targeted agents like sorafenib, systemic chemotherapy, hepatic artery infusion chemotherapy, or concurrent chemoradiotherapy.
- carcinoma /
- hepatocellular /
- alpha-fetoproteins

HTML全文

参考文献(31)

[1]CHEN JG.Trends in the incidence of liver cancer and its primaryprevention in China[J].J Clin Hepatol, 2012, 28 (4) :256-260. (in Chinese) 陈建国.中国肝癌发病趋势和一级预防[J].临床肝胆病杂志, 2012, 28 (4) :256-260.

[2]de LOPE CR, TREMOSINI S, FORNER A, et al.Management of HCC[J].J Hepatol, 2012, 56 (Suppl 1) :s75-s87.

[3]TAN DS, THOMAS GV, GARRETT MD, et al.Biomarker-drivenearly clinical trials in oncology:a paradigm shift in drug develop-ment[J].Cancer J, 2009, 15 (5) :406-420.

[4]GILLMORE R, STUART S, KIRKWOOD A, et al.EASL and mRECISTresponses are independent prognostic factors for survival in hepatocellularcancer patients treated with transarterial embolization[J].J Hepatol, 2011, 55 (6) :1309-1316.

[5]SHIM JH, LEE HC, KIM SO, et al.Which response criteria besthelp predict survival of patients with hepatocellular carcinoma fol-lowing chemoembolization?A validation study of old and new models[J].Radiology, 2012, 262 (2) :708-718.

[6]European Association for the Study of the Liver, European Organisa-tion for Research and Treatment of Cancer.EASL-EORTC clinicalpractice guidelines:management of hepatocellular carcinoma[J].JHepatol, 2012, 56 (4) :908-943.

[7]LEUNG TW, PATT YZ, LAU WY, et al.Complete pathologicalremission is possible with systemic combination chemotherapy for in-operable hepatocellular carcinoma[J].Clin Cancer Res, 1999, 5 (7) :1676-1681.

[8]NIE RH, LIU YY.Application of detection of tumor markers AFP, CA125, CA199 and CEA in diagnosis and treatment for patientswith hepatitis and liver cirrhosis[J].J Jilin Univ:Med Edit, 2012, 38 (1) :119-122. (in Chinese) 聂荣慧, 刘元元.肿瘤标志物AFP、CA125、CA199和CEA检测在肝炎、肝硬化患者诊断和治疗中的应用[J].吉林大学学报:医学报, 2012, 38 (1) :119-122.

[9]AOYAGI Y, SUZUKI Y, IGARASHI K, et al.Carbohydrate struc-tures of human alpha-fetoprotein of patients with hepatocellularcarcinoma:presence of fucosylated and non-fucosylated trianten-nary glycans[J].Br J Cancer, 1993, 67 (3) :486-492.

[10]NOMURA F, OHNISHI K, TANABE Y.Clinical features andprognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels.Analysis of 606 patients[J].Cancer, 1989, 64 (8) :1700-1707.

[11]IZUMI R, SHIMIZU K, KIRIYAMA M, et al.Alpha-fetoprotein pro-duction by hepatocellular carcinoma is prognostic of poor patient surviv-al[J].J Surg Oncol, 1992, 49 (3) :151-155.

[12]PENG SY, CHEN WJ, LAI PL, et al.High alpha-fetoprotein lev-el correlates with high stage, early recurrence and poor prognosis ofhepatocellular carcinoma:significance of hepatitis virus infection, age, p53 and beta-catenin mutations[J].Int J Cancer, 2004, 112 (1) :44-50.

[13]KOHLES N, NAGEL D, JUNGST D, et al.Prognostic relevance ofoncological serum biomarkers in liver cancer patients undergoingtransarterial chemoembolization therapy[J].Tumour Biol, 2012, 33 (1) :33-40.

[14]GIANNINI EG, MARENCO S, BORGONOVO G, et al.Alpha-fetoprotein has no prognostic role in small hepatocellular carcinomaidentified during surveillance in compensated cirrhosis[J].Hepa-tology, 2012, 56 (4) :1371-1379.

[15]XU XS, QU K, LIU C, et al.Highlights forα-fetoprotein in de-termining prognosis and treatment monitoring for hepatocellular car-cinoma[J].World J Gastroenterol, 2012, 18 (48) :7242-7250.

[16]TSAI MC, WANG JH, HUNG CH, et al.Favorable alpha-feto-protein decrease as a prognostic surrogate in patients with hepatocel-lular carcinoma after radiofrequency ablation[J].J GastroenterolHepatol, 2010, 25 (3) :605-612.

[17]KAO WY, CHIOU YY, HUNG HH, et al.Serum alpha-fetopro-tein response can predict prognosis in hepatocellular carcinoma pa-tients undergoing radiofrequency ablation therapy[J].Clin Radiol, 2012, 67 (5) :429-436.

[18]RIAZ A, RYU RK, KULIK LM, et al.Alpha-fetoprotein response afterlocoregional therapy for hepatocellular carcinoma:oncologic marker of ra-diologic response, progression, and survival[J].J Clin Oncol, 2009, 27 (34) :5734-5742.

[19]MEMON K, KULIK L, LEWANDOWSKI RJ, et al.Alpha-feto-protein response correlates with EASL response and survival in soli-tary hepatocellular carcinoma treated with transarterial therapies:asubgroup analysis[J].J Hepatol, 2012, 56 (5) :1112-1120.

[20]PARK WH, SHIM JH, HAN SB, et al.Clinical utility of des-gamma-carboxyprothrombin kinetics as a complement to radiologicresponse in patients with hepatocellular carcinoma undergoingtransarterial chemoembolization[J].J Vasc Interv Radiol, 2012, 23 (7) :927-936.

[21]LEE YK, KIM SU, KIM do Y, et al.Prognostic value of alpha-fetoprotein and des-gamma-carboxy prothrombin responses in pa-tients with hepatocellular carcinoma treated with transarterial chemo-embolization[J].BMC Cancer, 2013, 13 (1) :5.

[22]SHAO YY, LIN ZZ, HSU C, et al.Early alpha-fetoprotein re-sponse predicts treatment efficacy of antiangiogenic systemic therapyin patients with advanced hepatocellular carcinoma[J].Cancer, 2010, 116 (19) :4590-4596.

[23]YAU T, YAO TJ, CHAN P, et al.The significance of early alpha-fe-toprotein level changes in predicting clinical and survival benefits in ad-vanced hepatocellular carcinoma patients receiving sorafenib[J].On-cologist, 2011, 16 (9) :1270-1279.

[24]PERSONENI N, BOZZARELLI S, PRESSIANI T, et al.Useful-ness of alpha-fetoprotein response in patients treated with sorafenibfor advanced hepatocellular carcinoma[J].J Hepatol, 2012, 57 (1) :101-107.

[25]KIM BK, AHN SH, SEONG JS, et al.Early alpha-fetoprotein re-sponse as a predictor for clinical outcome after localized concurrentchemoradiotherapy for advanced hepatocellular carcinoma[J].LiverInt, 2011, 31 (3) :369-376.

[26]LEE MH, KIM SU, KIM do Y, et al.Early on-treatment predic-tions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepato-cellular carcinoma[J].J Gastroenterol Hepatol, 2012, 27 (2) :313-322.

[27]CHEN LT, LIU TW, CHAO Y, et al.alpha-fetoprotein response pre-dicts survival benefits of thalidomide in advanced hepatocellular carcinoma[J].Aliment Pharmacol Ther, 2005, 22 (3) :217-226.

[28]KEAM B, OH DY, LEE SH, et al.A Phase II study of 5-fluorou-racil and cisplatin systemic chemotherapy for inoperable hepatocellu-lar carcinoma with alpha fetoprotein as a predictive and prognosticmarker[J].Mol Med Report, 2008, 1 (3) :415-422.

[29]CHAN SL, MO FK, JOHNSON PJ, et al.New utility of an oldmarker:serial alpha-fetoprotein measurement in predicting radio-logic response and survival of patients with hepatocellular carcinomaundergoing systemic chemotherapy[J].J Clin Oncol, 2009, 27 (3) :446-452.

[30]VORA SR, ZHENG H, STADLER ZK, et al.Serum alpha-feto-protein response as a surrogate for clinical outcome in patients re-ceiving systemic therapy for advanced hepatocellular carcinoma[J].Oncologist, 2009, 14 (7) :717-725.

[31]BAI W, HAN GH.Comprehensive intervention treatment for hepa-tocellular carcinoma[J].J Clin Hepatol, 2013, 29 (1) :36-37, 41. (in Chinese) 白苇, 韩国宏.肝细胞癌的综合介入治疗[J].临床肝胆病杂志, 2013, 29 (1) :36-37, 41.

施引文献

资源附件(0)

访问统计